|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1994-9-8
|
|
pubmed:abstractText |
Sixty-five patients with high-risk trophoblast disease have been treated with the EMACO combination split regimen therapy in the 10 year period, 1981 to 1990. Four patients died but the remaining 61 (94%) remain free of disease up to 10 years later. Toxicity was manageable in most cases with minimal delay in treatment from myelosuppression. EMACO is a well tolerated regimen with a high cure rate in patients with high-risk gestational trophoblast disease (GTD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0004-8666
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
90-2
|
|
pubmed:dateRevised |
2009-11-11
|
|
pubmed:meshHeading |
pubmed-meshheading:8053886-Adolescent,
pubmed-meshheading:8053886-Adult,
pubmed-meshheading:8053886-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8053886-Australia,
pubmed-meshheading:8053886-Cyclophosphamide,
pubmed-meshheading:8053886-Dactinomycin,
pubmed-meshheading:8053886-Etoposide,
pubmed-meshheading:8053886-Female,
pubmed-meshheading:8053886-Humans,
pubmed-meshheading:8053886-Methotrexate,
pubmed-meshheading:8053886-Middle Aged,
pubmed-meshheading:8053886-Pregnancy,
pubmed-meshheading:8053886-Risk,
pubmed-meshheading:8053886-Trophoblastic Neoplasms,
pubmed-meshheading:8053886-Uterine Neoplasms,
pubmed-meshheading:8053886-Vincristine
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia.
|
|
pubmed:affiliation |
Royal Women's Hospital, Carlton, Victoria.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
